Qlife resolves on a partially guaranteed rights issue of approx. SEK 31.4 million and proposes an over-allotment option, enters bridge loan agreements and postpones the exercise period of warrants TO7

Qlife Holding AB has proposed a partially guaranteed rights issue of 15,679,521 shares at SEK 2.0 per share to raise approximately SEK 31.4m before costs, with subscription and guarantee commitments totalling roughly SEK 26.0m (82.9%). The company has also secured SEK 2.5m in bridge loans to cover near-term liquidity, proposed an over-allotment option of up to 3.0m shares, and will pay guarantee compensation (for bottom and top guarantees) as 15% in newly issued shares; full subscription would dilute existing holders by 50%. Proceeds are earmarked ~55% for commercial partnerships & sales, ~30% for EU/UK regulatory proceedings and ~15% for corporate purposes; the Board postponed TO7 warrant exercise to Feb 2027 and notes certain transactions may require FDI Act approval.

Analysis

Market structure: The SEK 31.4m rights issue (50% dilution; up to 54.4% if over-allotment used) materially increases free float and near-term selling pressure while preserving partnership upside via Hipro. Insider and management guarantees (~82.9% coverage, incl. top-down free guarantees) signal commitment but also financial strain: company needs cash primarily for commercial scaling (55%) and EU/UK regulation (30%) rather than R&D, shifting risk from science to execution and partner delivery over 6–18 months.

Risk assessment: Immediate risks (days–weeks) are share-price downside from issuance mechanics and failure of non‑secured guarantors to deliver (guarantees largely unsecured). Short/medium risks (weeks–months) include ISP delays under the FDI Act, JEQ set-off complexities, and warrant timing (TO7 deferred to Feb 2027) that can change cap table dynamics; long-term (quarters–years) tail risk is partner/licensing failure or regulatory non-approval that would make current capital insufficient.

Trade implications: Tactical trades should be rights-aware: subscribe pro rata to avoid 50% dilution if you believe the Hipro licensing and diabetes data convert to commercial deals within 12 months; otherwise sit out or hedge. Liquidity instruments (options/puts) should be used where available — buy protective puts or put spreads sized to 1–2% NAV given binary regulatory outcomes; avoid providing unsecured credit or buying guarantee-related shares pre-registration.

Contrarian angle: Consensus views dilution negative; but insiders converting claims/top-down guarantees free of charge reduces cash burn and aligns management incentives — if the market over-penalises post-issue price by >30% and the Info Document (circa 4 Mar) confirms concrete partner milestones and timelines, asymmetric upside exists. Conversely, if subscription falls below 70% or ISP filings delay >60 days, downside could exceed 50%.

Key Decisions for Investors

• If you hold QLIFE (Nasdaq First North: QLIFE), participate pro rata in the Rights Issue at SEK 2.00 if your investment horizon is 12–18 months and you target ≥100% upside (price target SEK 4.00) driven by partner rollouts; cap allocation to 1–3% NAV and set hard stop-loss at -30% from entry.
• New entrants without existing shares: avoid outright cash buy of QLIFE shares until post-issue price discovery (wait for Rights Issue outcome on ~23 Mar and Information Document ~4 Mar). Consider buying subscription rights or BTAs during 5–19 Mar if market trades rights cheaply (<SEK0.40 implied) to effectively lower entry below SEK2.
• Risk-managed hedge: if you cannot subscribe, buy a 3–6 month put or put-spread (or OTC collar where available) sized to 1–2% NAV to protect downside from issuance and regulatory risk; trigger to add core long only if post-issue price drops >30% and Info Doc confirms partner KPIs.
• Event-driven short/avoid: establish a small opportunistic short (or synthetic short via buy put) if post-issue subscription <70% or if ISP approval is denied/delayed >60 days — position size max 0.5–1% NAV due to borrow and liquidity risk; cover within 30–90 days on any positive regulatory confirmation.